Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.34B 51.51B 47.29B 89.31B 6,077B 90.69B 607B 238B 3,025B 239B 234B 10,145B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.38B 65.51B 60.15B 114B 7,729B 115B 772B 303B 3,848B 304B 297B 12,902B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.53%	-3.95%	+55.23%	+152.74%	1,024B
JOHNSON & JOHNSON	+0.21%	-2.68%	+55.61%	+53.02%	618B
ABBVIE INC.	-2.51%	-3.25%	+32.76%	+67.76%	443B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	349B
NOVARTIS AG	-0.14%	-0.24%	+34.41%	+39.01%	297B
ASTRAZENECA PLC	-0.69%	-0.30%	+11.55%	+12.93%	264B
NOVO NORDISK A/S	-7.37%	-4.40%	-2.54%	-43.87%	209B
AMGEN INC.	-0.64%	+2.43%	+30.52%	+64.49%	208B
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.96%	+71.01%	162B
Average	-1.38%	-1.20%	+30.11%	+49.75%	397.08B
Weighted average by Cap.	-0.99%	-1.93%	+39.24%	+72.95%

	2018	2019
Net sales	15.79B 13.72B 12.77B 11.73B 22.15B 1,507B 22.49B 151B 59.1B 750B 59.29B 57.99B 2,516B	16.09B 13.99B 13.02B 11.95B 22.57B 1,536B 22.92B 153B 60.22B 765B 60.42B 59.1B 2,564B
Net income	-5.1B -4.43B -4.12B -3.79B -7.15B -487B -7.26B -48.61B -19.08B -242B -19.14B -18.72B -812B	-5.27B -4.58B -4.26B -3.92B -7.39B -503B -7.51B -50.27B -19.73B -251B -19.8B -19.36B -840B
Net Debt	21.89B 19.03B 17.71B 16.26B 30.71B 2,090B 31.19B 209B 81.94B 1,040B 82.21B 80.41B 3,488B	17.3B 15.04B 14B 12.86B 24.28B 1,652B 24.65B 165B 64.77B 822B 64.99B 63.56B 2,758B

End-of-day quote NYSE Other stock markets
- ^USD	-